30 results about "Anti-angiogenic drugs" patented technology

Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.

The invention relates to a gambogic acid ester derivative as well as a preparation method and a use thereof. The structural formula of the derivative is as shown in formula (I) in the specification. The preparation method of the gambogic acid ester derivative comprises the following steps of: dissolving gambogic acid, gemcitabine and triphenylphosphine in anhydrous tetrahydrofuran under the protection of nitrogen gas; injecting a THF (Tetrahydrofuran) solution containing Diethyl Azodicarboxylate (DEAD) and reacting for 12-24 hours; and obtaining a product by washing, drying, rotary steaming and column chromatography. The derivative can be used for preparing a composition, an antineoplastic drug, an antifungal drug or an anti-angiogenic drug or is combined with other anti-cancer active components. The derivative disclosed by the invention not only has good activity to a plurality of tumor cells, but also has good targeting performance to the tumor cells, and therefore, a foundation is laid for developing novel drugs.

The invention relates to an injection anticancer long circulating targeting liposome which is characterized in that anti-angiogenic drug is combined with anticancer drug, the liposome modified by polypeptide with tumor targeting function and hydrophilic polyethyleneglycol is adopted for loading and transporting the two drugs to tumor positions, and the tumor curative effect is enhanced through the different releasing rates and action mechanism of the two drugs.

The present invention belongs to the field of marine natural medicines, and relates to new medicinal uses of a Rhodomela confervoides effective component bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane. According to the present invention, the kinase activity experiment results prove that the compound affects the activity of an angiogenesis-related receptor tyrosine kinase, and can inhibit the activities of multiple kinases; with the human umbilical vein endothelial cell proliferation experiment and the angiogenesis experiment, the influence of the compound on the angiogenesis is observed, and the experiment results prove that the compound can effectively provide the anti-angiogenesis effect; and the bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane adopted as the pharmaceutical effective component can be added with the pharmaceutically acceptable carrier so as to prepare the anti-angiogenesis pharmaceutical composition.

The invention relates to the medicine field and discloses application of triptonide to anti-angiogenesis drugs. In-vitro and in-vivo tests for suppressing tumor neovascularization are carried out by adopting triptonide and the results show that the Chinese herbal medicine monomer triptonide can induce silencing of key genes for tumor neovascularization, promote tumor cell aging, differentiation and apoptosis, eliminate or reduce the neovascularization capacities of tumor cells, normalize and eliminate tumor vessels and improve the anticancer curative effects. Effective dose of triptonide and pharmaceutically acceptable auxiliary components can be used for preparing tablets, granules, capsules, suspension agents, syrup, emulsion or other common drug preparations. The drug preparations can be used for anti-angiogenesis. Besides, the extracts containing triptonide can be used for preparing the anti-angiogenesis drug preparations.

The invention belongs to the technical field of medicine, and relates to an application of oxadiazole piperazine compounds in preparing an anti-angiogenesis drug. The two oxadiazole piperazine compounds are N'-(3-allyl-2-phenol methylene)-2-(4-benzyl piperazine-1-group) acethydrazide and (E)-N / -(4-((2-((benzo [d][1,3]dioxolane-5-group) methyl) thiazole-4-group) methoxy)-2-phenol methylene)-2-(4-((3-(4-((4-fluorobenzene oxygroup) methyl) phenyl)-1,2,4-oxadiazole-5-group) methyl) piperazine-1-group) acethydrazide hydrochloride. According to the application, the two oxadiazole piperazine compounds have obvious inhibiting effects on a human umbilical vein endothelial cell (HUVEC) microtubule forming experiment, a Transwell chamber migration experiment, a rat arterial ring experiment and the like, can obviously inhibit endothelial cell microtubule forming, can obviously inhibit resistive migration of an endothelial cell, and can obviously inhibit rat arterial ring capillary generation.